File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma

TitleAlbumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma
Authors
KeywordsCancer
Cell-free circulating nucleic acid
HCC
Liver transplantation
Plasma mRNA
Prognosis
Issue Date2008
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com
Citation
Transplantation, 2008, v. 85 n. 1, p. 81-87 How to Cite?
AbstractBACKGROUND. Currently, hepatocellular carcinoma (HCC) patients are selected for liver transplantation based on radiological assessment (size and number of tumor nodules) and/or pathological features (tumor grade and vascular invasion). The former criteria have limited power on prognosis, whereas the latter do not provide complete information until explant is available. METHODS. This study aims to investigate whether quantitative measurement of plasma mRNA derived from cancer can provide preoperative prognostic information. Preoperative plasma samples obtained from 72 HCC patients who had undergone liver transplantation were studied. The patients were selected for liver transplantation largely based on the Milan criteria before 2002 and UCSF criteria after 2002. Real-time quantitative reverse transcriptase polymerase chain reaction with Taqman system was used to measure the albumin mRNA levels in plasma. RESULTS. Fifteen patients (21%) had HCC recurrences. Patients with a high plasma albumin mRNA level (>14.6) had a significantly higher recurrence rate (log-rank test, P=0.001). High plasma albumin mRNA level predicted 2-year HCC recurrence with sensitivity and specificity of 73% and 70%, respectively. By multivariate analysis, plasma albumin mRNA level (adjusted hazard ratio=5.9, P=0.002) and vascular invasion (adjusted hazard ratio=6.0, P=0.001) were the only independent risk factors for prediction of HCC recurrence. CONCLUSIONS. Plasma albumin mRNA quantification predicts posttransplant HCC recurrence. It may supplement the current selection criteria of HCC patients for liver transplantation. © 2008 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/88563
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, STen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLee, YTen_HK
dc.contributor.authorChow, JPen_HK
dc.contributor.authorNg, IOen_HK
dc.contributor.authorFong, DYen_HK
dc.contributor.authorLo, CMen_HK
dc.date.accessioned2010-09-06T09:45:00Z-
dc.date.available2010-09-06T09:45:00Z-
dc.date.issued2008en_HK
dc.identifier.citationTransplantation, 2008, v. 85 n. 1, p. 81-87en_HK
dc.identifier.issn0041-1337en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88563-
dc.description.abstractBACKGROUND. Currently, hepatocellular carcinoma (HCC) patients are selected for liver transplantation based on radiological assessment (size and number of tumor nodules) and/or pathological features (tumor grade and vascular invasion). The former criteria have limited power on prognosis, whereas the latter do not provide complete information until explant is available. METHODS. This study aims to investigate whether quantitative measurement of plasma mRNA derived from cancer can provide preoperative prognostic information. Preoperative plasma samples obtained from 72 HCC patients who had undergone liver transplantation were studied. The patients were selected for liver transplantation largely based on the Milan criteria before 2002 and UCSF criteria after 2002. Real-time quantitative reverse transcriptase polymerase chain reaction with Taqman system was used to measure the albumin mRNA levels in plasma. RESULTS. Fifteen patients (21%) had HCC recurrences. Patients with a high plasma albumin mRNA level (>14.6) had a significantly higher recurrence rate (log-rank test, P=0.001). High plasma albumin mRNA level predicted 2-year HCC recurrence with sensitivity and specificity of 73% and 70%, respectively. By multivariate analysis, plasma albumin mRNA level (adjusted hazard ratio=5.9, P=0.002) and vascular invasion (adjusted hazard ratio=6.0, P=0.001) were the only independent risk factors for prediction of HCC recurrence. CONCLUSIONS. Plasma albumin mRNA quantification predicts posttransplant HCC recurrence. It may supplement the current selection criteria of HCC patients for liver transplantation. © 2008 Lippincott Williams & Wilkins, Inc.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.comen_HK
dc.relation.ispartofTransplantationen_HK
dc.rightsTransplantation. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subjectCanceren_HK
dc.subjectCell-free circulating nucleic aciden_HK
dc.subjectHCCen_HK
dc.subjectLiver transplantationen_HK
dc.subjectPlasma mRNAen_HK
dc.subjectPrognosisen_HK
dc.subject.meshAlbumins - genetics - metabolismen_HK
dc.subject.meshCarcinoma, Hepatocellular - blood - diagnosis - surgeryen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKaplan-Meier Estimateen_HK
dc.subject.meshLiver Neoplasms - blood - diagnosis - surgeryen_HK
dc.subject.meshLiver Transplantationen_HK
dc.subject.meshNeoplasm Recurrence, Local - blood - diagnosisen_HK
dc.subject.meshPredictive Value of Testsen_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshRNA, Messenger - blooden_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshSensitivity and Specificityen_HK
dc.titleAlbumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0041-1337&volume=85&issue=1&spage=81&epage=87&date=2008&atitle=Albumin+mRNA+in+plasma+predicts+post-transplant+recurrence+of+patients+with+hepatocellular+carcinomaen_HK
dc.identifier.emailCheung, ST: stcheung@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailNg, IO: iolng@hku.hken_HK
dc.identifier.emailFong, DY: dytfong@hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.authorityCheung, ST=rp00457en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityNg, IO=rp00335en_HK
dc.identifier.authorityFong, DY=rp00253en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.tp.0000298003.88530.11en_HK
dc.identifier.pmid18192916-
dc.identifier.scopuseid_2-s2.0-38149126488en_HK
dc.identifier.hkuros140972en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-38149126488&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume85en_HK
dc.identifier.issue1en_HK
dc.identifier.spage81en_HK
dc.identifier.epage87en_HK
dc.identifier.isiWOS:000252530600014-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridCheung, ST=7202473497en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLee, YT=22734702300en_HK
dc.identifier.scopusauthoridChow, JP=49761108400en_HK
dc.identifier.scopusauthoridNg, IO=7102753722en_HK
dc.identifier.scopusauthoridFong, DY=35261710300en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats